Early Data From Ionis/Biogen’s BIIB080 Keeps Tau Alzheimer’s Hopes Alive
Unique Antisense Approach To Tau
While many other approaches have failed, Ionis and Biogen hope their novel oligonucleotide can stop toxic tau tangles forming in the brain.
You may also be interested in...
In an attempt to show Biogen has more than its troubled Alzheimer’s drug Aduhelm to drive revenue growth, the company’s R&D Day highlighted several programs from its portfolio of 33 clinical-stage assets.
Citing the FDA approval of Biogen’s Aduhelm, AbbVie tells quarterly call it will end development of anti-tau Alzheimer’s candidate and seek to develop a quick-acting beta-amyloid therapy.
Deal Snapshot: The company is looking to expand its pipeline beyond Alzheimer’s, where it hit a speedbump in September with the failure of a tau-targeting drug.